Clinical Trial Update: Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating N-acetylcysteine (NAC) for impulse control disorders in Parkinson's disease; current status unclear.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impulse Control Disorder
• Parkinson Disease

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Centre Hospitalier Universitaire, Amiens | Conditions: Impulse Control Disorder, Parkinson | Phase 3 | Status: UNKNOWN